Rituximab as frontline monotherapy in untreated hairy cell leukemia patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Rituximab as frontline monotherapy in untreated hairy cell leukemia patients

Published:2015-02-13 Issue:6 Volume:94 Page:1069-1070
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Akinosoglou K.,Melachrinou M.,Makatsoris T.,Sakellakis M.,Papakonstantinou C.,Gogos C. A.,Solomou E. E.

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00277-015-2328-9.pdf

Reference8 articles.

1. Leclerc M, Suarez F, Noel MP, Vekhoff A, Troussard X, Claisse JF, Thieblemont C, Maloisel F, Beguin Y, Tamburini J, Barbe C, Delmer A (2015) Rituximab therapy for hairy cell leukemia: a retrospective study of 41 cases. Ann Hematol 94(1):89–95. doi: 10.1007/s00277-014-2175-0

2. Jones G, Parry-Jones N, Wilkins B, Else M, Catovsky D (2012) Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant*. Br J Haematol 156(2):186–195

3. Maevis V, Mey U, Schmidt-Wolf G, Schmidt-Wolf IG (2014) Hairy cell leukemia: short review, today's recommendations and outlook. Blood Cancer J 4:e184

4. Dasanu CA, Alexandrescu DT (2010) Risk of additional cancers in untreated and treated hairy cell leukemia patients. Expert Opin Pharmacother 11(1):41–50

5. Malfuson JV, Fagot T, Konopacki J, Souleau B, Cremades S, de Revel T (2010) Which role for rituximab in hairy cell leukemia? Reflections on six cases. Acta Haematol 123(2):110–116

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prompt Hematological Recovery in Response to a Combination of Pegylated Interferon α-2a and Rituximab in a Profoundly Immuno-Suppressed Hairy Cell Leukemia Patient with a Mycobacterial Infection at Onset: Benefits and Drawbacks of Rapid Immune Reconstitution;Hematology Reports;2022-04-13

2. Potential breakthroughs with investigational drugs for hairy cell leukemia;Expert Opinion on Investigational Drugs;2015-09-02

3. Are Cladribine and Rituximab Enough for the Treatment of Relapsed Hairy Cell Leukemia?;International Journal of Immunotherapy and Cancer Research;2015-08-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3